Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nationial Cancer Center manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active for the organization. This action is assigned to 1 distinct art unit, which suggests a focused technical review process for the center's current patent applications.
The prosecution involves a distinct examiner, EDGINGTONGIORDANO, FRANCESCA. This examiner is the busiest for the portfolio, holding a busiest examiner pending action. Because the pending office action is the only action in the portfolio, the practitioner is interacting with the examiner. The distinct art unit and examiner structure indicates a lack of diversification in the current examination phase. The busiest examiner pending action accounts for the total active workload, meaning the practitioner can focus on the specific preferences of the assigned examiner during prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EDGINGTONGIORDANO, FRANCESCA | 1 | 70.8% | +31.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276582 | CCR4-Targeting Chimeric Antigen Receptor Cell Therapy | EDGINGTONGIORDANO, FRANCESCA | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276582 | CCR4-Targeting Chimeric Antigen Receptor Cell Therapy | EDGINGTONGIORDANO, FRANCESCA | 23d overdue |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18276582 | CCR4-Targeting Chimeric Antigen Receptor Cell Therapy | EDGINGTONGIORDANO, FRANCESCA | 1643 | §102§103§112 | Non-Final OA | 23d overdue | Pending | Aug 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial